drugset / Trial / NCT03633084
RBM-007 in Subjects witH ExudatIve Age-related Macular Degeneration
Non-randomizedSingle-groupOpen-labelTreatment
Summary
This is an open label, non-controlled, dose-escalating study assessing the safety, tolerability, and bioactivity of a single intravitreal (i.vt.) injection of RBM-007 in approximately nine subjects with exudative age-related macular degeneration.
Timeline
- Start
- 2018-08-29
- Primary completion
- 2019-06-26
- Completion
- 2019-06-26
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | RBM-007 | Aptamer | 0.2 mg | Intravitreal |
| Subject | RBM-007 | Aptamer | 1 mg | Intravitreal |
| Subject | RBM-007 | Aptamer | 2 mg | Intravitreal |